MX2023002843A - Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios. - Google Patents
Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios.Info
- Publication number
- MX2023002843A MX2023002843A MX2023002843A MX2023002843A MX2023002843A MX 2023002843 A MX2023002843 A MX 2023002843A MX 2023002843 A MX2023002843 A MX 2023002843A MX 2023002843 A MX2023002843 A MX 2023002843A MX 2023002843 A MX2023002843 A MX 2023002843A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- autoimmune disorders
- treatment regimen
- novel
- regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/25—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
- Application Of Or Painting With Fluid Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062706795P | 2020-09-10 | 2020-09-10 | |
| US202062706819P | 2020-09-11 | 2020-09-11 | |
| US202063198971P | 2020-11-25 | 2020-11-25 | |
| US202063199265P | 2020-12-16 | 2020-12-16 | |
| US202163149196P | 2021-02-12 | 2021-02-12 | |
| US202163175318P | 2021-04-15 | 2021-04-15 | |
| PCT/EP2021/074928 WO2022053608A1 (en) | 2020-09-10 | 2021-09-10 | Novel treatment regimen for the treatment of autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002843A true MX2023002843A (es) | 2023-03-31 |
Family
ID=78080246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002843A MX2023002843A (es) | 2020-09-10 | 2021-09-10 | Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios. |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20240226284A1 (https=) |
| EP (1) | EP4210710A1 (https=) |
| JP (1) | JP2023541877A (https=) |
| KR (1) | KR20230066402A (https=) |
| AU (1) | AU2021342333A1 (https=) |
| BR (1) | BR112023003432A2 (https=) |
| CA (1) | CA3194812A1 (https=) |
| IL (1) | IL301246A (https=) |
| MX (1) | MX2023002843A (https=) |
| WO (1) | WO2022053608A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023003432A2 (pt) | 2020-09-10 | 2023-03-21 | Merck Patent Gmbh | Regime de tratamento para o tratamento de doenças autoimunes |
| AU2023293707A1 (en) | 2022-06-15 | 2025-01-23 | Vektor Pharma Tf Gmbh | Sublingual formulation of anticancer compound for use in the treatment of autoimmune neurodegenerative diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3273787D1 (en) | 1981-02-04 | 1986-11-20 | Japan Found Cancer | Human interferon-beta gene |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| JPS62153300A (ja) | 1985-12-26 | 1987-07-08 | Teijin Ltd | ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法 |
| US5106837A (en) | 1988-03-16 | 1992-04-21 | The Scripps Research Institute | Adenosine derivatives with therapeutic activity |
| US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| DE68926888T2 (de) | 1988-01-22 | 1997-01-09 | Zymogenetics Inc | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
| US4964848A (en) | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ES2145744T5 (es) | 1991-01-18 | 2008-02-01 | Amgen Inc. | Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral. |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| EP0801571B1 (en) | 1994-12-22 | 2002-09-04 | Ortho Pharmaceutical Corporation | Soluble 2-chloro-2'-deoxyadenosine formulations |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US6800616B2 (en) | 1998-02-26 | 2004-10-05 | Supergen, Inc. | Treatment of HIV infections |
| EE05214B1 (et) | 1998-04-28 | 2009-10-15 | Applied Research Systems ARS Holding N.V. | Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon |
| BR9915548A (pt) | 1998-10-16 | 2001-08-14 | Biogen Inc | Proteìnas de fusão de interferon-beta e usos |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| FR2792480B1 (fr) | 1999-04-19 | 2001-06-15 | France Telecom | Systeme de mise en oeuvre de services telephoniques |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| US7754855B1 (en) | 1999-07-13 | 2010-07-13 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
| EP1556400B1 (en) | 2002-09-25 | 2013-05-01 | Brigham Young University | Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine |
| GB2394658A (en) | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| WO2004075903A1 (en) | 2003-02-25 | 2004-09-10 | Applied Research Systems Ars Holding N.V. | Combined use of ribavirin and interferon beta in demyelinating diseases |
| WO2004087100A2 (en) | 2003-03-28 | 2004-10-14 | Ivax Corporation | Cladribine formulations for improved oral and transmucosal delivery |
| DK2272503T3 (da) | 2003-03-28 | 2013-05-21 | Ares Trading Sa | Orale formuleringer af cladribin |
| TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
| MXPA04010902A (es) * | 2004-11-03 | 2006-05-08 | Alvaro Raul Lara Rodriguez | Vacuna recombinante a partir de las proteinas ge, gi y gb del virus de varicela zoster como tratamiento y prevencion de esclerosis multiple. |
| EP2275110B1 (en) | 2004-12-22 | 2013-07-10 | Merck Serono SA | Cladribine regimen for treating Multiple Sclerosis |
| WO2007135172A2 (en) | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| WO2017035357A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Phosphonate compounds for treatment of medical disorders |
| AR113906A1 (es) | 2017-11-24 | 2020-06-24 | Merck Patent Ges Mit Beschraenkter Haftung | Régimen con cladribina para tratar formas progresivas de la esclerosis múltiple |
| BR112023003432A2 (pt) | 2020-09-10 | 2023-03-21 | Merck Patent Gmbh | Regime de tratamento para o tratamento de doenças autoimunes |
-
2021
- 2021-09-10 BR BR112023003432A patent/BR112023003432A2/pt unknown
- 2021-09-10 CA CA3194812A patent/CA3194812A1/en active Pending
- 2021-09-10 AU AU2021342333A patent/AU2021342333A1/en active Pending
- 2021-09-10 US US18/044,568 patent/US20240226284A1/en active Pending
- 2021-09-10 EP EP21786771.2A patent/EP4210710A1/en active Pending
- 2021-09-10 KR KR1020237011881A patent/KR20230066402A/ko active Pending
- 2021-09-10 JP JP2023515725A patent/JP2023541877A/ja active Pending
- 2021-09-10 MX MX2023002843A patent/MX2023002843A/es unknown
- 2021-09-10 WO PCT/EP2021/074928 patent/WO2022053608A1/en not_active Ceased
- 2021-09-10 IL IL301246A patent/IL301246A/en unknown
-
2024
- 2024-03-08 US US18/599,308 patent/US12539329B2/en active Active
- 2024-06-20 US US18/748,995 patent/US12533408B2/en active Active
-
2025
- 2025-11-10 US US19/384,362 patent/US20260069681A1/en active Pending
- 2025-12-23 US US19/430,755 patent/US20260115278A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260115278A1 (en) | 2026-04-30 |
| US20260069681A1 (en) | 2026-03-12 |
| CA3194812A1 (en) | 2022-03-17 |
| US20240226284A1 (en) | 2024-07-11 |
| US20240335529A1 (en) | 2024-10-10 |
| EP4210710A1 (en) | 2023-07-19 |
| WO2022053608A1 (en) | 2022-03-17 |
| IL301246A (en) | 2023-05-01 |
| JP2023541877A (ja) | 2023-10-04 |
| AU2021342333A1 (en) | 2023-04-06 |
| KR20230066402A (ko) | 2023-05-15 |
| US12539329B2 (en) | 2026-02-03 |
| BR112023003432A2 (pt) | 2023-03-21 |
| US20240374715A1 (en) | 2024-11-14 |
| US12533408B2 (en) | 2026-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210436A (es) | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales | |
| MX2023002843A (es) | Nuevo regimen de tratamiento para el tratamiento de trastornos autoinmunitarios. | |
| AR103130A1 (es) | Sonda de vitrectomía con un escáner de fibra óptica | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| AR115583A1 (es) | Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado | |
| CL2023002218A1 (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| MX2023001443A (es) | Tratamiento con oligonucleotidos de pacientes con hepatitis b. | |
| CO2022000426A2 (es) | Inhibidores de calicreína plasmática | |
| MX2022014034A (es) | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. | |
| EA201692180A1 (ru) | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации | |
| MX2019005065A (es) | Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa. | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| CO2022005113A2 (es) | Métodos de tratamiento para modificar la hemodinámica | |
| CL2023001580A1 (es) | Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| MX2022002833A (es) | Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos. | |
| MX2021011598A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| EA202192961A1 (ru) | Ребамипид для применения в профилактике и/или лечении синуклеинопатий | |
| MX2022010093A (es) | Tafoxiparina para el tratamiento de la preeclampsia. | |
| PY2013134A (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfa | |
| UY31786A1 (es) | Inhibidores de la expresion y la actividad del pai-1 para el tratamiento de trastornos oculares | |
| DOP2020000049A (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
| MX2021011183A (es) | Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria. | |
| BR112021026662A2 (pt) | Métodos para aliviar a preocupação associada à pterígio sobre a aparência do olho |